Current stock page

Catalysts

UTHR Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

UTHRUnited Therapeutics Corporation

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$591.17−$2.14 (−0.36%)

Latest quote

  • Momentum
    68
  • Value
    78
  • Quality
    81
  • Risk resilience
    83
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 24, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 76/100

Momentum 68/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 35.55%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 68/100AIQ Edge 10/10 Sector Leader
Beat rate
50%
4 of 8 reported periods
Average surprise
-1.7%
Across covered historical reports
Latest result
-5.0%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—$6.01$5.71-5.0%$781.14M$832.5M
Aug 5, 2026—$6.86$7.27+6.0%$804.65M$783.3M
May 6, 2026—$7.00$5.82-16.9%$797.4M$781.5M
Feb 25, 2026—$7.13$7.70+8.0%$813.08M$790.2M
Oct 29, 2025—$6.89$7.16+3.9%$814.8M$799.5M
Jul 30, 2025—$7.29$6.41-12.1%$801.87M$798.6M
Apr 30, 2025—$6.29$6.63+5.4%$778.66M$794.4M
Feb 26, 2025—$6.40$6.19-3.3%$734.73M$735.9M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
12
Buy
3
Hold
1
Sell
12-month analyst target
$687.40
+16.28% versus current price
Based on 16 analyst observations. Targets are estimates, not predictions.
Low target
$368.00
-37.75% vs latest price
Average target
$687.40
+16.28% vs latest price
High target
$850.00
+43.78% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 24, 2027

Next known earnings or reporting date.

EPS estimate$4.95

Current analyst expectation for the upcoming report.

Revenue estimate$861.62M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score68

Where event reaction would show up first.

AIQ score76/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
16
Average target
$687.40
Target upside
16.28%
Target range
$368.00 - $850.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
0
Negative
0
seekingalpha.com · Nov 4, 2026

United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript

United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call November 4, 2026 9:00 AM ESTCompany ParticipantsHarrison Silvers - Manager of Investor...

insidermonkey.com · Oct 20, 2026

United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?

United Therapeutics Corporation (NASDAQ:UTHR) develops treatments for pulmonary arterial hypertension, a rare and dangerous high blood pressure in the lungs, with its Tyvaso franchise at the core.

gurufocus.com · Oct 19, 2026

UTHR Maintained by Leerink Partners -- Price Target Raised to $725

United Therapeutics Corp (UTHR) Analyst Rating Update On October 10, 2023, Leerink Partners maintained an Outperform rating for United Therapeutics (UTHR). A

gurufocus.com · Oct 19, 2026

United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial on Treprostinil SMI in PH-COPD

On October 19, 2026, United Therapeutics Corp (NASDAQ: UTHR) announced that the U.S. Food and Drug Administration has approved the initiation of its SUMMIT clin

Open full news and sentiment

UTHR Catalysts FAQ

What are the next catalysts for UTHR stock?

UTHR's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move UTHR stock?

Upcoming events that could move UTHR include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could UTHR's next earnings report affect the stock?

UTHR's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive UTHR stock higher?

UTHR could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt UTHR stock?

UTHR could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.